Clinical trial report: TMC278 (Rilpivirine) versus efavirenz as initial therapy in treatment-Naïve, HIV-1-infected patients

Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents

Hughes C.A., Robinson L., Tseng A., MacArthur R.D., New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir, Expert Opinion in Pharmacotherapy, 10, pp. 2445-66, (2009)

Tseng A., MacArthur R.D., Profile of etravirine for the treatment of HIV infection, Therapeutics and Clinical Risk Management, 6, pp. 49-58, (2010)

MacArthur R.D., Huppler Hullsiek K., Peng G., Et al., CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the International Network for Strategic Initiative in Global HIV Trials (INSIGHT), XVII International HIV Drug Resistance Workshop

Van Den Berg-Wolf M., Hullsiek K.H., Peng G., Et al., CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and the International Network for Strategic Initiative in Global HIV Trials (INSIGHT): Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons, HIV Clinical Trials, 9, pp. 324-36, (2008)

Rimsky L., Eron J., Clotet B., Et al., Characterization of the resistance profile of TMC278: 48 week analysis of the Phase III studies ECHO and THRIVE, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents

Hughes C.A., Robinson L., Tseng A., MacArthur R.D., New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir, Expert Opinion in Pharmacotherapy, 10, pp. 2445-66, (2009)

Tseng A., MacArthur R.D., Profile of etravirine for the treatment of HIV infection, Therapeutics and Clinical Risk Management, 6, pp. 49-58, (2010)

MacArthur R.D., Huppler Hullsiek K., Peng G., Et al., CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the International Network for Strategic Initiative in Global HIV Trials (INSIGHT), XVII International HIV Drug Resistance Workshop

Van Den Berg-Wolf M., Hullsiek K.H., Peng G., Et al., CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and the International Network for Strategic Initiative in Global HIV Trials (INSIGHT): Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons, HIV Clinical Trials, 9, pp. 324-36, (2008)

Rimsky L., Eron J., Clotet B., Et al., Characterization of the resistance profile of TMC278: 48 week analysis of the Phase III studies ECHO and THRIVE, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy